Key Events This Week
18 May: Stock opens at Rs.29.55, down 1.57% amid broader market weakness
19 May: Sharp rebound with 4.97% gain to Rs.31.02 on rising volumes
20 May: Continued momentum with 5.00% rise to Rs.32.57 ahead of upgrade
21 May: MarketsMOJO upgrades stock to Buy; closes at Rs.34.19 (+4.97%)
22 May: Slight profit-taking at Rs.33.54 (-1.90%) as Sensex gains 0.21%
18 May 2026: Weak Start Amid Market Decline
The week began with Sudarshan Pharma’s stock closing at Rs.29.55, down 1.57% from the previous Friday’s close of Rs.30.02. This decline occurred alongside a broader Sensex drop of 0.35%, reflecting cautious sentiment in the market. Trading volume was relatively low at 32,000 shares, indicating subdued investor activity as the stock consolidated near its recent levels.
19 May 2026: Strong Rebound on Rising Volumes
On 19 May, the stock rebounded sharply, gaining 4.97% to close at Rs.31.02. This recovery was accompanied by a significant increase in volume to 184,000 shares, signalling renewed buying interest. The Sensex also advanced 0.25%, but Sudarshan Pharma’s outperformance was notable, suggesting early signs of positive momentum building in the stock ahead of upcoming fundamental developments.
20 May 2026: Momentum Builds Ahead of Upgrade
The upward trend continued on 20 May with the stock rising 5.00% to Rs.32.57 on volumes of 176,000 shares. This price action preceded the official upgrade by MarketsMOJO, reflecting growing market anticipation. The Sensex gained 0.28%, but Sudarshan Pharma’s 5% daily gain underscored its strengthening technical position. The stock was approaching its 52-week high of Rs.35.19, signalling robust investor confidence.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
21 May 2026: Upgrade to Buy Spurs 4.97% Gain
MarketsMOJO upgraded Sudarshan Pharma from 'Hold' to 'Buy' on 20 May, citing strong technical and financial performance. The stock responded positively, closing at Rs.34.19 on 21 May, a 4.97% gain from the previous day’s close. This upgrade reflected improvements in technical indicators such as a bullish weekly MACD and Bollinger Bands, alongside robust quarterly financial results including a 120.9% increase in Profit Before Tax compared to the prior four-quarter average.
The upgrade also highlighted the company’s attractive valuation metrics, with a Return on Capital Employed of 10.5% and an Enterprise Value to Capital Employed ratio of 2.5, signalling efficient capital use and reasonable pricing. The stock’s 3-year return of 386.05% far outpaces the Sensex’s 22.01%, underscoring its strong market position.
22 May 2026: Minor Profit-Taking Amid Sensex Gains
On the final trading day of the week, Sudarshan Pharma’s stock retreated 1.90% to close at Rs.33.54 on volume of 116,000 shares. This slight pullback followed four consecutive days of strong gains and coincided with a Sensex rise of 0.21%. The minor correction is typical after a sustained rally and does not detract from the overall positive weekly performance. The stock remains well above its opening price for the week, maintaining a strong technical outlook.
Want to dive deeper on Sudarshan Pharma Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Daily Price Performance Compared to Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-18 | Rs.29.55 | -1.57% | 35,114.86 | -0.35% |
| 2026-05-19 | Rs.31.02 | +4.97% | 35,201.48 | +0.25% |
| 2026-05-20 | Rs.32.57 | +5.00% | 35,299.20 | +0.28% |
| 2026-05-21 | Rs.34.19 | +4.97% | 35,340.31 | +0.12% |
| 2026-05-22 | Rs.33.54 | -1.90% | 35,413.94 | +0.21% |
Key Takeaways from the Week
Positive Signals: Sudarshan Pharma’s 11.73% weekly gain significantly outperformed the Sensex’s 0.50% rise, driven by a strong technical momentum shift and a fundamental upgrade to a 'Buy' rating. The stock’s bullish daily moving averages, weekly MACD, and Bollinger Bands indicate a strengthening uptrend. Robust quarterly financials, including a 120.9% increase in Profit Before Tax, underpin the positive outlook. The company’s valuation metrics remain attractive, with a ROCE of 10.5% and reasonable enterprise value ratios.
Cautionary Notes: Despite the strong rally, the stock experienced a minor pullback on 22 May, reflecting typical profit-taking after rapid gains. The monthly MACD remains mildly bearish, suggesting investors should monitor longer-term momentum for potential consolidation. Elevated leverage, with a Debt to EBITDA ratio of 5.77, poses a risk to financial flexibility. Additionally, the absence of domestic mutual fund holdings may indicate liquidity or scale concerns despite strong fundamentals.
Conclusion: Renewed Confidence Amid Strong Fundamentals
The week ending 22 May 2026 marked a significant positive phase for Sudarshan Pharma Industries Ltd, highlighted by an 11.73% price appreciation and a MarketsMOJO upgrade to 'Buy'. The convergence of bullish technical indicators and robust financial performance has propelled the stock well above its opening price for the week, signalling renewed investor confidence. While minor profit-taking and some cautionary technical signals warrant attention, the overall outlook remains constructive. Sudarshan Pharma’s ability to outperform the Sensex consistently over multiple time horizons reinforces its position as a compelling micro-cap specialty chemicals stock with strong growth potential.
53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today
